Jeff Yass’s Revelation Biosciences REVB Stock Holding History

Jeff Yass’s Portfolio REVB Stock Details REVB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-69	Closed	-$11.3K	–	13041
2024 Q3	$11.3K	Buy	+69	New	+$16.6K	﹤0.01%	11709
2023 Q4	–	Sell	-2	Closed	-$8.56K	–	13153
2023 Q3	$8.56K	Buy	+2	New	+$8.82K	﹤0.01%	11736
2021 Q4	–	Hold	0	–	-$126K	–	13770
2021 Q3	–	Hold	0	–	–	–	11916

Other funds holding REVB

XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

TSS

Two Sigma Securities New York $1.16B AUM 36.23% 1-Year Est. Return

StoneX Group New York $2.48B AUM 33.54% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Jeff Yass's REVB Position: Q4 2024 in Review

Jeff Yass sold out of Revelation Biosciences (REVB) in Q4 2024, closing a stake of 69 shares — an estimated $11.3K sold.

Jeff Yass first reported a position in REVB in Q3 2023 and held it in 2 quarters. The position peaked at $11.3K in Q3 2024. 8 funds tracked by Wall St. Rank hold REVB as of Q4 2024.

Jeff Yass reported no remaining Revelation Biosciences position as of Q4 2024 after selling out during the quarter.
Jeff Yass sold 69 Revelation Biosciences shares in Q4 2024, an estimated $11.3K.
Jeff Yass first reported a position in Revelation Biosciences in Q3 2023 and held it in 2 quarters.
Jeff Yass's Revelation Biosciences position peaked at $11.3K in Q3 2024.
8 funds tracked by Wall St. Rank held Revelation Biosciences as of Q4 2024.

Based on Susquehanna International Group's 13F filing for Q4 2024, filed 14 Feb 2025.